The World Health Organization (WHO) has approved another COVID-19 vaccine for emergency use listing (EUL): Corbevax, a recombinant protein–based vaccine developed by scientists at Texas Children’s Hospital and Baylor College of Medicine.

During the EUL process, WHO advisory groups evaluated the vaccine to ensure that it meets the WHO’s standards for protection and safety, with a goal of speeding the availability of products to people who need them. Corbevax is the 14th COVID vaccine to receive the WHO EUL.

In a press release, Texas Children’s Hospital said 100 million doses of Corbevax have been administered in India. The vaccine is made on a platform that uses a Pichia pastoris yeast strain to express the RBD protein of SARS-CoV-2, used as an antigen and optimized with an adjuvant, or immune-booster.

https://www.cidrap.umn.edu/covid-19/who-grants-emergency-listing-corbevax-covid-vaccine

https://theconversation.com/corbevax-a-new-patent-free-covid-19-vaccine-could-be-a-pandemic-game-changer-globally-174672

 

Corbevax is NOT an mRNA based product but IS spike based using a recombinant DNA technology (similar to the Novavax shot).